science

Palopegteriparatide

Palopegteriparatide is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Palopegteriparatide rather than just read about it. In short: Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of hypoparathyroidism. It is a transiently pegylated parathyroid hormone.

Key takeaways

Palopegteriparatide belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Palopegteriparatide to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Palopegteriparatide from memory before moving on to harder problems.

Reference excerpt

Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of hypoparathyroidism. It is a transiently pegylated parathyroid hormone. It is a parathyroid hormone analog. Palopegteriparatide was approved for medical use in the European Union in November 2023, and in the United States in August 2024.

Medical uses Palopegteriparatide is indicated for the treatment of adults with hypoparathyroidism.

Adverse effects The US Food and Drug Administration (FDA) prescription label for palopegteriparatide includes warnings for a potential risk of risk of unintended changes in serum calcium levels related to number of daily injections and total delivered dose, serious hypocalcemia and hypercalcemia (blood calcium levels that are too high), osteosarcoma (a rare bone cancer) based on findings in rats, orthostatic hypotension (dizziness when standing), and a risk of a drug interaction with digoxin (a medicine for certain heart conditions).

History The effectiveness of palopegteriparatide was evaluated in a 26-week, randomized, double-blind, placebo-controlled trial that enrolled 82 adults with hypoparathyroidism. Prior to randomization, all participants underwent an approximate four-week screening period in which calcium and active vitamin D supplements were adjusted to achieve an albumin-corrected serum calcium concentration between 7.8 and 10.6 mg/dL, a magnesium concentration ≥1.3 mg/dL and below the upper limit of the reference range, and a 25(OH) vitamin D concentration between 20 and 80 ng/mL. During the double-blind period, participants were randomized to either palopegteriparatide (N = 61) or placebo (N= 21), at a starting dose of 18 mcg/day, co-administered with conventional therapy (calcium and active vitamin D). Study drug and conventional therapy were subsequently adjusted according to the albumin-corrected serum calcium levels. At the end of the trial, 69% of the participants in the palopegteriparatide group compared to 5% of the participants in the placebo group were able to maintain their calcium level in the normal range, without needing active vitamin D and high doses of calcium (calcium dose ≤ 600 mg/day). The FDA granted the application for palopegteriparatide orphan drug and priority review designations.

Society and culture

Legal status In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yorvipath, intended for the treatment of chronic hypoparathyroidism in adults. The applicant for this medicinal product is Ascendis Pharma Bone Diseases A/S. Palopegteriparatide was approved for medical use in the European Union in November 2023. Palopegteriparatide was granted an orphan drug designation by the US Food and Drug Administration (FDA) in 2018, and by the EMA in 2020.

Brand names Palopegteriparatide is the international nonproprietary name. Palopegteriparatide is sold under the brand name Yorvipath.

References

External links Palopegteriparatide Global Substance Registration System Palopegteriparatide NCI Thesaurus Clinical trial number NCT04701203 for "A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism (PaTHway)" at ClinicalTrials.gov

Illustrations

Worked examples

Example 1 — a first encounter with Palopegteriparatide

Start with the simplest possible case. Write down what Palopegteriparatide claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Palopegteriparatide before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Palopegteriparatide ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Palopegteriparatide

In research: Palopegteriparatide appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Palopegteriparatide in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Palopegteriparatide is common in secondary-school and first-year university syllabi. It links to neighbouring topics Orphan drugs, Peptides, so understanding it makes those chapters shorter.
In everyday life: Look for Palopegteriparatide outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Palopegteriparatide” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Palopegteriparatide in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Palopegteriparatide means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Palopegteriparatide out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Palopegteriparatide in simple terms?

Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of hypoparathyroidism. It is a transiently pegylated parathyroid hormone.

Why does Palopegteriparatide matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Palopegteriparatide?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Palopegteriparatide.